Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.

Innovative Insights into Duloxetine’s Role in Relieving Knee Osteoarthritis Pain and Enhancing Quality of Life
Discover how duloxetine, a medication originally developed for depression, is emerging as an effective option for managing knee osteoarthritis pain. This article explains how duloxetine works differently from traditional painkillers by targeting pain signals in the nervous system, offering significant relief for patients who struggle with persistent discomfort. Clinical studies highlight its potential to improve both pain and mobility, while also positively impacting mood and sleep. Learn about its benefits, possible side effects, and the growing role duloxetine plays in comprehensive osteoarthritis care for enhanced quality of life.